Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BioNTech News

Emma Rose 2025 Nov 15, 00:00

US Stock Market Outlook: Jitters and Potential Catalysts

Ava Grace 2025 Nov 15, 00:00

Fiscal Firefighting: US & Japan's Unorthodox Inflation Strategy

Sophia Claire 2025 Nov 15, 00:00

Guggenheim Partners Sees Fed Rate Cut in December Amid Economic Slowdown Concerns

Ava Grace 2025 Nov 15, 00:00

US Government Shutdown Aftermath: Rate Cut Concerns and Market Uncertainty

Sophia Claire 2025 Nov 15, 00:00

El-Erian Flags Economic Worries: Low-Income Consumers & Debt Refinancing

Frances Wang 2025 Nov 13, 16:00

Commodity market today: Gold prices are rising, what is XAU/USD prediction?

Frances Wang 2025 Nov 13, 16:00

AI stocks are trending: Qualcomm stock, Nvidia (NVDA), AMD stock

Ghko B 2025 Nov 12, 16:00

VOO performance analysis: What is the VOO ETF performance prediction?

Ghko B 2025 Nov 12, 16:00

Easy stocks for beginners: MSFT stock, AAPL stock, NVIDIA (NASDAQ: NVDA)

Frances Wang 2025 Nov 12, 16:00

Stellar climbs 4% today: Stellar (XLM) Price Prediction for 2025, 2026, 2030

Latest news

Show more
Sophia Claire 2025 Nov 15, 03:30

Czech National Bank's Crypto Experiment: Exploring Digital Assets and Coinbase Investment

Emma Rose 2025 Nov 15, 02:40

Bitcoin & Ethereum Plunge: US Market Pressures Unveiling Underlying Causes

Sophia Claire 2025 Nov 15, 02:30

Crypto Market Bottoms: Contrarian Indicators and Sentiment Analysis

Ava Grace 2025 Nov 15, 01:40

Crypto Weekly Recap: Market Trends and Regulatory Updates

Liam James 2025 Nov 15, 00:40

CFTC Likely to Dominate Crypto Oversight, Says ProCap BTC CIO

Liam James 2025 Nov 15, 00:00

Russian Oil Exports Disrupted at Novorossiysk Port: Drone Attack Fuels Price Surge

Emma Rose 2025 Nov 15, 00:00

Economists Fear Data 'Black Hole' in Wake of US Government Shutdown

Ava Grace 2025 Nov 15, 00:00

US Government Reopens, Deep Divisions Remain After Shutdown

Info

Spread

0.6780

Spread (%)

0.6605 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

14:31 - 20:59

Tuesday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

24978511872

Shares Outstanding

240455450

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-1.66

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Ghko B 2025 Nov 13, 16:00

Which broker is best for bitcoin trading: Cheapest Ways to Buy Bitcoin In 2026

Ghko B 2025 Nov 13, 16:00

Crypto day trading strategy: How to day trade crypto as a beginner?

Ghko B 2025 Nov 13, 16:00

Commodity trading strategy: WTI Oil faces potential decline, what’s next?

Trustpilot